在患有类风湿性关节炎的患者中,对甲索特酸剂量进行药理动力学-药理动力学建模和模拟
Jiun Ming Tan1, Richard N Upton2, David J R Foster3
1University of South Australia (UniSA: Clinical and Health Sciences, Centre for Pharmaceutical Innovation), Adelaide, South Australia, Australia.
British journal of clinical pharmacology
|July 5, 2024
概括
在4周内,甲铁酸的加载剂量会比标准剂量更有效地增加红细胞甲铁酸多胺酸 (ery-MTX-PG) 和改善类风湿性关节炎 (RA) 疾病活性评分 (DAS-28-3).
科学领域:
- 药理动力学和药理动力学
- 类风湿性关节炎的治疗方法
- 药物剂量方案 药物剂量方案
背景情况:
- 甲托雷克萨特 (MTX) 是类风湿性关节炎 (RA) 的基石疗法.
- 红细胞甲基酸多重胺酸 (ery-MTX-PG) 是影响MTX疗效的活性代谢物.
- 了解 ery-MTX-PG 与疾病活性之间的关系对于优化 RA 治疗至关重要.
研究的目的:
- 开发一个人群的药理动力学-药理动力学 (PK-PD) 模型,用于 RA 患者的 ery-MTX-PG.
- 为了将血红-MTX-PG度与28关节疾病活动评分 (DAS-28-3) 相关联.
- 评估一种新的加载剂量方案与标准剂量对治疗反应的影响.
主要方法:
- 使用117名RA患者的数据开发了一个非线性混合效应群体PK-PD模型.
- 该模型包含了血红-MTX-PG度 (PK) 和DAS-28-3分数 (PD).
- 蒙特卡洛模拟将加载剂量方案 (50毫克加载,然后每周20毫克) 与标准剂量 (10毫克2周,然后每周20毫克) 相比较.
主要成果:
- 血红-MTX-PG (3-5谷氨酸) 每增加40nmol/L,与DAS-28-3.3减少1单位相关.
- 普雷尼索隆使用 (前4周) 和患者年龄是影响治疗反应的显著共变量.
- 加重剂量治疗方案导致患者在第4周 (87.6%对39.8%) 和第10周 (64.7%对57.0%) 达到良好/中等反应的比例更高.
结论:
- 一种甲托雷克萨特加载剂量方案有效地增加了血红-MTX-PG度.
- 加重剂量导致RA患者在4周内比标准剂量更好的治疗反应.
- 开发的PK-PD模型提供了对优化甲状腺胺剂量策略的洞察力.
相关概念视频
Pharmacokinetic Models: Overview
647
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
647
Pharmacokinetic Models: Comparison and Selection Criterion
66
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
66
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
68
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
68
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
37
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
37
Mechanistic Models: Overview of Compartment Models
79
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
79
Analysis of Population Pharmacokinetic Data
252
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
252


